Alto Neuroscience, which uses AI to identify biomarkers to develop targeted psychiatric medicine options, announced it had closed a $25 million equity investment with new investor Alpha Wave Ventures and entered into a credit facility for up to $35 million with K2 HealthVentures.
The Series B extension brings the round to about $60 million. The company will use the funds to continue growing its...
